liraglutide glp 1 analogue is a GLP-1 Receptor Agonist for Type 2 Diabetes Research Liraglutide activates key brain circuits

The most significant weight loss occurs after 12 to 16 weeks of consistent use

June 2024: Structure Therapeutics reported positive Phase IIa obesity data for GSBR-1290, an oral non-peptide small-molecule GLP-1 receptor agonist, achieving 6.2% placebo-adjusted mean weight loss at 12 weeks

Tashkin DP, Shapiro BJ, Frank IM

The sustained action of glucagon causes hyperglycaemia, and glucose-mediated inhibition of glucagon secretion is impaired in patients with type 2 diabetes (see comprehensive reviews in [49, 50])

Clinical adverse events associated with sodium-glucose cotransporter 2 inhibitors: a meta-analysis involving 10 randomized clinical trials and 71 553 individuals